Düsseldorf, Germany – April 7th, 2025
LenioBio is pleased to unveil ALiCE® for High-Throughput Protein Expression (ALiCE® HTPE), the first eukaryotic cell-free expression platform specifically engineered for rapid antibody discovery and screening. By offering an end-to-end service covering DNA template generation, lead generation, purification and analysis, this new solution slashes production timelines from 4 weeks to as little as 3 days.
As drug development pipelines grow in complexity and speed, discovery teams face intense pressure to generate high-quality leads faster. ALiCE® HTPE removes common bottlenecks, such as transfection inefficiencies and slow expression, by enabling rapid, parallel synthesis of diverse antibody formats, including mAbs, VHH nanobodies, Fabs, and multi-specifics.
Designed to integrate seamlessly into automated, high-throughput workflows, ALiCE HTPE supports both linear and plasmid DNA templates. It yields antibodies with CHO-equivalent binding affinities and native post-translational modifications, including disulfide bonds and glycosylation.
“We are thrilled to expand our platform capabilities with ALiCE® HTPE, supporting life science and biopharmaceutical innovators rapidly translate AI-generated protein designs into reliable antibody constructs. What once took weeks can now be done in just a few days.”, says André Goerke, CEO, LenioBio GmbH.
The new HTPE offer builds on LenioBio’s expanding ALiCE® portfolio and its mission to overcome the limitations of cell-based protein expression. With this offering, LenioBio provides all researchers a faster, scalable, and open platform democratizing protein expression regardless of cell culture capabilities and propels next-generation antibody discovery worldwide.
About LenioBio
LenioBio GmbH is a life sciences biotech company dedicated to transforming protein production through its proprietary ALiCE® technology. By eliminating the limitations and bottlenecks of traditional cell-based systems, LenioBio empowers researchers to explore new frontiers in protein expression and accelerate the development of cutting-edge therapeutics and diagnostics.
Please visit our website at www.leniobio.com and follow us on LinkedIn.